Whitehawk Therapeutics (WHWK) Total Non-Current Liabilities (2020 - 2025)
Whitehawk Therapeutics (WHWK) reported Total Non-Current Liabilities of $14.5 million for Q4 2025, down 17.69% year-over-year from $17.6 million in Q4 2024, and up 47.42% on a QoQ basis from $9.8 million in Q3 2025.
Whitehawk Therapeutics (WHWK) has 6 years of Total Non-Current Liabilities data on file, last reported at $14.5 million in Q4 2025.
- Quarterly Total Non-Current Liabilities fell 17.69% year-over-year to $14.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.5 million (down 17.69% YoY) and the FY2025 annual result came in at $14.5 million, down 17.69% from the prior year.
- Total Non-Current Liabilities advanced to $14.5 million in Q4 2025 per WHWK's latest filing, from $9.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $27.2 million in Q4 2023 and bottomed at $8.8 million in Q2 2025.
- The 5-year median for Total Non-Current Liabilities is $16.4 million (2024), against an average of $16.4 million.
- Peak annual rise in Total Non-Current Liabilities reached 17.69% in 2025, while the deepest fall reached 40.08% in 2025.
- Tracing WHWK's Total Non-Current Liabilities over 5 years: stood at $21.5 million in 2021, then decreased by 7.94% to $19.8 million in 2022, then surged by 37.54% to $27.2 million in 2023, then slumped by 35.22% to $17.6 million in 2024, then declined by 17.69% to $14.5 million in 2025.
- Per Business Quant, the three latest WHWK Total Non-Current Liabilities figures stand at $14.5 million (Q4 2025), $9.8 million (Q3 2025), and $8.8 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Whitehawk Therapeutics | 312.26 Mn | 189.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.52 Mn |
| Sep 30, 2025 | 9.85 Mn |
| Jun 30, 2025 | 8.76 Mn |
| Mar 31, 2025 | 12.27 Mn |
| Dec 31, 2024 | 17.64 Mn |
| Sep 30, 2024 | 16.44 Mn |
| Dec 31, 2023 | 27.23 Mn |
| Jun 30, 2022 | 19.80 Mn |
| Dec 31, 2021 | 21.50 Mn |
| Dec 31, 2020 | 31.16 Mn |